Disclosure: I am long CLSN. I wrote this article myself,

New Post Public Reply Private Reply Replies (2) Message Board
bjones111
Disclosure: I am long CLSN. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Every once in a while, there is a sector and/or industry that captivates the investment market. During the 1990s, the computer and software sector created a windfall of profits for investors. In the early part of the 21st century, the dot com era helped to score a large payday for those who were fortunate enough to get in early. Over the past couple of years, emerging market and commodity stocks have proven to be a wise move. And now investors are wondering what is next? Look no further than biotechnology, specifically stocks that focus on cancer treatments.

2013 is poised to be a breakthrough year for several biotechnology companies, especially in the cancer treatment space. These biotechnology companies will have major catalysts that will not only cause a jump in their share prices but will have ripple affects across the biotechnology space. As the industry becomes more competitive with more companies looking to find that mythical cure, the biotechnology space will continue to be a driver of both medicine and investor return for years to come. 2013 will be just the beginning and the following three companies are poised to benefit.

Of course, these companies and the industry in general are not without risks. The biotechnology industry is perhaps the most rewarding industry to be involved with since investor profits usually mean a medical breakthrough for those who are suffering. However, the industry is perhaps the riskiest with companies constantly facing make or break decisions. Additionally, the industry has intense competition. Many companies are trying to develop a drug and/or treatment for various diseases but the fact of the matter is that very few will succeed. The steps facing a start-up biotechnology company are daunting. Companies must face Phase I, Phase II, and Phase III drug trials, demonstrating both efficacy and safety control. The companies must navigate these trials over several years while being able to have cash on hand to fund the trials. Normally this means a series of fundraising efforts which dilute the ownership of the existing shareholders. Should the company be able to navigate through these muddy waters, they must face a critical FDA decision, which are never easy. Considering all the risks involved, I still think the three companies below are poised to breakout.

1) Celsion Corporation (CLSN) - The company will release Phase III trials of ThermoDox, a potential breakthrough in the treatment of liver cancer. The release of these results is expected by the end of January 2013. Should the results be favorable, and many think they will, the stock has the potential to climb by several hundred percent before the expected FDA decision by the end of 2013.



The stock is not without risk though. As you can see in the stock chart above, Celsion has had an incredible run since the beginning of the summer. The early investors are most likely riding free shares at this point while new investors will have to pay a high premium to get in. There is also the chance that Phase III trials could prove unsuccessful. If this were to occur, the stock would likely fall below 2, and probably 1. Because the company was able to jump directly from Phase I to Phase III, there is a lot of mystery surrounding the results that are due in just a few weeks.

2) Cellceutix Corporation (CTIX.OB) - An emerging bio-pharmaceutical company, the company received widespread attention with its promising results from the early development of a compound for the treatment of autism, KM-391. Additionally, Phase I clinical trials for Kevetrin, the company's compound for the treatment of drug-resistant cancers, are about to begin. While most cancer treatments are derived from another compound, Kevetrin is completely unique. Add to this is the fact that several industry goliaths are backing Kevetrin, most notably Best Israel and the Dana Farber cancer center. This company might revolutionize the cancer industry.



Cellceutix is not without risk however. First, the company trades on the OTCBB. This is the wild wild west of trading and pretty much anything goes. Investors should be aware of this and understand that there may be wild swings in the share price until the company is able to uplist to the NYSE or Nasdaq. Second, the company is a developmental biotechnology company that has not even begun Phase I trials yet. With already 90 million outstanding shares, the company may need to raise funds in the future which will dilute the original investors. Given these risks, it is important to manage one's risk and only put a portion of one's funds in this company.

3) Threshold Pharmaceuticals (THLD) - A development staged company, focused on the discovery and development of drugs for the treatment of various forms of cancer. Its primary clinical development product is TH-302, which has already successfully passed Phase I and Phase II trials. During 2013, the company will release the final Phase III trial results. With the backing of Merck, and a very small float, the rewards could be off the chart for those investors willing to jump in now. Threshold has had a rough few months because of concerns that competitors will get their competing drugs to market first. I think this concern is overblown as Threshold has shown that its trial results put its drug at or near the top in terms of efficacy.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 342

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 73

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 103

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 562

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 344

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 129

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Investment Growth: What $100 in UBS Stock Means Today

Updated Category News Views 106

Understanding UBS Group AG's Stock Performance UBS Group AG (NYSE: UBS) has shown significant resilience and growth in the stock market over the past five years. The company has outperformed the overall market by an impressive 9.96%, yielding an average annual return of 24.36%. This substantial performance highlights UBS's strength in a competitive landscape, positioning...

Continue Reading
Perella Weinberg's Financial Results Showcase Strategic Moves

Updated Category News Views 208

Overview of Financial Performance Recently, Perella Weinberg Partners (NASDAQ: PWP) shared its financial results for the third quarter, showcasing a nuanced landscape of both challenges and opportunities. The firm reported revenues totaling $165 million during the quarter, reflecting a 41% decline from the same period a year prior, when it achieved record revenues of $278...

Continue Reading
Kensington Vanguard Welcomes New Leaders in Phoenix Office

Updated Category News Views 625

Kensington Vanguard Expands Leadership Team in Phoenix Kensington Vanguard National Land Services (KV), a well-regarded title insurance agency, is thrilled to announce new additions to its Phoenix office. Distinguished professionals Chadwick Campbell and Scott Schmidt have joined KV, enhancing the company's drive for service excellence in the region. Introducing Chadwick...

Continue Reading
Investor Alert: Funko, Inc. Faces Investigation Over Stock Decline

Updated Category News Views 238

Investor Alert: Funko, Inc. Faces Investigation Over Stock Decline FUNKO, INC. (NASDAQ: FNKO) is currently at the center of an investigation concerning potential securities fraud. Pomerantz LLP, a firm known for its expertise in corporate and securities law, is investigating claims on behalf of investors who are concerned about recent developments involving the company....

Continue Reading
CVB Financial Corp. Continues Tradition of Quarterly Dividends

Updated Category News Views 187

CVB Financial Corp. Continues Tradition of Quarterly Dividends CVB Financial Corp. (NASDAQ: CVBF) recently declared an impressive cash dividend of twenty cents ($0.20) per share for the first quarter. This announcement represents the company's 142nd consecutive quarterly dividend, highlighting a consistent commitment to rewarding investors. The decision was made during a...

Continue Reading